As we look towards the 3rd quarter of the 2026/27 financial year, the Additional Roles Reimbursement Scheme (ARRS) continues to be the primary vehicle for workforce expansion in the UK. However, for many PCN leaders, the ‘use it or lose it’ nature of the funding has created a cycle of reactive recruitment that often prioritises headcount over actual clinical impact.
With the 2026/27 GP Contract now mandating same-day responses for clinically urgent needs, the stakes for your ARRS spend have changed. It is no longer enough to simply fill a vacancy; the role must contribute immediately to practice capacity without draining the very GP time it was meant to save.
Why Traditional Hiring is Stalling
Recent workforce analyses indicate a significant “recruitment plateau” in primary care. According to The Health Foundation, the initial surge of ARRS expansion has peaked, leaving PCNs to contend with a saturated and highly competitive labour market. The easy wins of early recruitment have passed; today, the pool of experienced, “primary care ready” clinical pharmacists is thinner than ever.
Beyond the difficulty of finding staff, the traditional direct-hire model has revealed three structural flaws that lead to “lost” funding:
- The Management Overhang: PCN Clinical Directors are frequently overwhelmed by supervision requirements. BMA guidance continues to emphasise that appropriate clinical oversight is a non-negotiable safety requirement, yet this burden frequently falls back onto already overstretched GP partners, negating the efficiency gains of the new role.
- Training Lead-Times: A newly recruited pharmacist can take 6–12 months to become fully autonomous, particularly while navigating the mandatory CPPE pathway. During this window, the PCN pays for a role that is effectively still “in training.”
- Governance Gaps: Monitoring the Quality and Outcomes Framework (QOF) impact and medication safety audits across a disparate team is a significant administrative weight. Without a unified system, quality assurance becomes fragmented and reactive.
Why We Built a Managed Service
At Medacy, our model didn’t start with a boardroom strategy; it was designed over years of encountering these exact friction points while supplying PCNs and practices. We realised that the body in a chair approach was failing both the clinician and the practice.
We have now been delivering our evolved Managed Clinical Infrastructure model in Primary care for years, addressing the ROI gap for PCNs and Practices across the country.
Here is how our lessons learned translate into your ROI:
- Zero-Supervision Guarantee: We discovered that GP partners were spending hours every week supervising ARRS staff. We solved this by providing internal senior clinical oversight. Our pharmacists are supervised by Medacy’s own senior leads, ensuring the practice only deals with clinical queries—not management overhead.
- Plug-and-Play Clinical Autonomy: We noticed the delay in ROI while pharmacists trained for their IP status. Consequently, we made it a baseline requirement: every Medacy pharmacist is a qualified Independent Prescriber from day one.
- Centralised Governance (The Virtual Practice): Managing multiple sites is hard. We built a centralised management model with a robust Quality Management System (RADAR) to handle incident reporting and clinical audits across all our sites. This moves the burden of quality assurance from the PCN Lead to us.
Proving ROI in the Era of Accountability
In 2026, Integrated Care Boards (ICBs) are scrutinising ARRS spend with unprecedented rigour. To justify funding, PCNs must demonstrate how these roles impact access and patient safety. A payroll record is no longer a sufficient metric of success.
The Medacy service includes monthly performance reporting built around the metrics that matter most in the current contract:
- Clearing Backlogs: Rapid processing of discharge letters and clinical correspondence.
- QOF & IIF Optimisation: Targeted interventions for the new 2026 diabetes 8-care-process indicators..
- Cost Savings: Identifying prescribing efficiencies and medication optimisation opportunities that go beyond the basic ARRS reimbursement.
From Recruitment to Results
The 2026/27 contract year provides a unique opportunity to stabilise your workforce. By moving away from the direct-hire management trap and toward a managed service, PCNs can recover unspent funding and—more importantly—reclaim the GP time currently being lost to the “supervision tax.”
Success in the current climate isn’t defined by how many people you have on the payroll, but by how much clinical capacity those people actually create.
Ready to audit your ARRS impact? Contact Medacy today to discuss how our managed clinical pharmacy service can move your PCN from “filling roles” to delivering measurable results.
